Switch theme
Sign up to access all valuation multiples
Rohto Pharmaceutical Co Ltd is a Japan-based manufacturer and marketer of pharmaceutical products, cosmetics, and functional foods. It undertakes manufacture and sales activities mainly in the health and beauty care categories. The company comprises the four geographical reportable segments of Japan, America, Europe, and Asia. In each segment, it manufactures and sales eye care products including eye drops and eyewash preparations, skincare products including dermal medicines, lip balm, sunscreens, and functional cosmetics, among others, internal medicines and food products including gastrointestinal medicines, traditional Chinese herbal medicines and supplements, and other products and services, such as in-vitro test kits.
1949
8.0K+
LTM Revenue $2.2B
LTM EBITDA $372M
$3.0B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Rohto Pharmaceutical has a last 12-month revenue (LTM) of $2.2B and a last 12-month EBITDA of $372M.
In the most recent fiscal year, Rohto Pharmaceutical achieved revenue of $2.1B and an EBITDA of $390M.
Rohto Pharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Rohto Pharmaceutical valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $2.2B | XXX | $2.1B | XXX | XXX | XXX |
| Gross Profit | $1.2B | XXX | $1.2B | XXX | XXX | XXX |
| Gross Margin | 56% | XXX | 57% | XXX | XXX | XXX |
| EBITDA | $372M | XXX | $390M | XXX | XXX | XXX |
| EBITDA Margin | 17% | XXX | 18% | XXX | XXX | XXX |
| EBIT | $271M | XXX | $269M | XXX | XXX | XXX |
| EBIT Margin | 12% | XXX | 13% | XXX | XXX | XXX |
| Net Profit | $215M | XXX | $214M | XXX | XXX | XXX |
| Net Margin | 10% | XXX | 10% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 1, 2025, Rohto Pharmaceutical's stock price is JPY 2045 (or $14).
Rohto Pharmaceutical has current market cap of JPY 462B (or $3.2B), and EV of JPY 435B (or $3.0B).
See Rohto Pharmaceutical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3.0B | $3.2B | XXX | XXX | XXX | XXX | $0.94 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 1, 2025, Rohto Pharmaceutical has market cap of $3.2B and EV of $3.0B.
Rohto Pharmaceutical's trades at 1.5x EV/Revenue multiple, and 7.9x EV/EBITDA.
Equity research analysts estimate Rohto Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Rohto Pharmaceutical has a P/E ratio of 14.9x.
See valuation multiples for Rohto Pharmaceutical and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3.2B | XXX | $3.2B | XXX | XXX | XXX |
| EV (current) | $3.0B | XXX | $3.0B | XXX | XXX | XXX |
| EV/Revenue | 1.4x | XXX | 1.5x | XXX | XXX | XXX |
| EV/EBITDA | 8.1x | XXX | 7.9x | XXX | XXX | XXX |
| EV/EBIT | 11.1x | XXX | 11.1x | XXX | XXX | XXX |
| EV/Gross Profit | 2.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | 14.9x | XXX | 14.9x | XXX | XXX | XXX |
| EV/FCF | -13.7x | XXX | 16.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialRohto Pharmaceutical's last 12 month revenue growth is 8%
Rohto Pharmaceutical's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Rohto Pharmaceutical's rule of 40 is 26% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Rohto Pharmaceutical's rule of X is 37% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Rohto Pharmaceutical and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 8% | XXX | 8% | XXX | XXX | XXX |
| EBITDA Margin | 17% | XXX | 18% | XXX | XXX | XXX |
| EBITDA Growth | 7% | XXX | 4% | XXX | XXX | XXX |
| Rule of 40 | 26% | XXX | 26% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 37% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 19% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 5% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 44% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Acme United | XXX | XXX | XXX | XXX | XXX | XXX |
| EZZ Life Science | XXX | XXX | XXX | XXX | XXX | XXX |
| Live Verdure | XXX | XXX | XXX | XXX | XXX | XXX |
| Lavipharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Sarantis Group | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Rohto Pharmaceutical acquired XXX companies to date.
Last acquisition by Rohto Pharmaceutical was XXXXXXXX, XXXXX XXXXX XXXXXX . Rohto Pharmaceutical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Rohto Pharmaceutical founded? | Rohto Pharmaceutical was founded in 1949. |
| Where is Rohto Pharmaceutical headquartered? | Rohto Pharmaceutical is headquartered in Japan. |
| How many employees does Rohto Pharmaceutical have? | As of today, Rohto Pharmaceutical has 8.0K+ employees. |
| Who is the CEO of Rohto Pharmaceutical? | Rohto Pharmaceutical's CEO is Mr. Kunio Yamada. |
| Is Rohto Pharmaceutical publicy listed? | Yes, Rohto Pharmaceutical is a public company listed on TKS. |
| What is the stock symbol of Rohto Pharmaceutical? | Rohto Pharmaceutical trades under 4527 ticker. |
| When did Rohto Pharmaceutical go public? | Rohto Pharmaceutical went public in 1962. |
| Who are competitors of Rohto Pharmaceutical? | Similar companies to Rohto Pharmaceutical include e.g. Acme United, EZZ Life Science, Live Verdure, Lavipharm. |
| What is the current market cap of Rohto Pharmaceutical? | Rohto Pharmaceutical's current market cap is $3.2B |
| What is the current revenue of Rohto Pharmaceutical? | Rohto Pharmaceutical's last 12 months revenue is $2.2B. |
| What is the current revenue growth of Rohto Pharmaceutical? | Rohto Pharmaceutical revenue growth (NTM/LTM) is 8%. |
| What is the current EV/Revenue multiple of Rohto Pharmaceutical? | Current revenue multiple of Rohto Pharmaceutical is 1.4x. |
| Is Rohto Pharmaceutical profitable? | Yes, Rohto Pharmaceutical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Rohto Pharmaceutical? | Rohto Pharmaceutical's last 12 months EBITDA is $372M. |
| What is Rohto Pharmaceutical's EBITDA margin? | Rohto Pharmaceutical's last 12 months EBITDA margin is 17%. |
| What is the current EV/EBITDA multiple of Rohto Pharmaceutical? | Current EBITDA multiple of Rohto Pharmaceutical is 8.1x. |
| What is the current FCF of Rohto Pharmaceutical? | Rohto Pharmaceutical's last 12 months FCF is -$219M. |
| What is Rohto Pharmaceutical's FCF margin? | Rohto Pharmaceutical's last 12 months FCF margin is -10%. |
| What is the current EV/FCF multiple of Rohto Pharmaceutical? | Current FCF multiple of Rohto Pharmaceutical is -13.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
